Novo touts one-year data for its diabetes tandem therapy

June 14, 2014 5:11 PM

26 0

Combine the blockbuster GLP-1 drug Victoza with a long-acting insulin and you get a treatment greater than the sum of its parts, according to Novo Nordisk ($NVO), which unveiled promising new data on its diabetes cocktail IDegLira.

In a 52-week study on 1,663 Type 2 diabetes patients, those taking the combo therapy had a baseline blood glucose of 6.4%, beating out the 7.1% for patients on Victoza and the 6.9% taking Novo's long-acting insulin degludec, marketed as Tresiba. The American Diabetes Association's healthy threshold ...

Read more

To category page